Abstract
No public abstract is available from the verified source records.
Open public full textRights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureRamsay Hafer, Francesco Iadevaia, Thomas Z. Rohan, Teresa Duong, Maria Poluch, Gina Keiffer, Michael Li, Andres Ferber, Luca Laurenti, Alan S. Khoo, Pierluigi Porcu
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Diagnosis and treatment of chronic lymphocytic leukemia: a review
10.1001/jama.2023.1946 · 2023
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
10.3324/haematol.2017.182907 · 2018
Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia
10.1001/jamaoncol.2014.218 · 2015
Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial
10.1200/jco.21.01210 · 2021
Managing toxicities of Bruton tyrosine kinase inhibitors
10.1182/hematology.2020000118 · 2020
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
10.1056/nejmoa1509388 · 2015
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
10.1056/nejmoa1400376 · 2014
Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia
10.1056/nejmoa1509981 · 2016
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
10.1182/blood.2018884940 · 2020
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
10.1182/bloodadvances.2023009739 · 2023
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
2023
A global federated real-world data and analytics platform for research
10.1093/jamiaopen/ooad035 · 2023
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
10.1182/blood.2022018818 · 2023
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
10.1038/s41375-021-01485-x · 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
10.1182/bloodadvances.2021006434 · 2022
No additional external references are available.